Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts. Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.](/p.php?pid=staticchart&s=N%5EONXX&p=8&t=15)
Onyx Pharmaceuticals Reports Second Quarter and Six Month 2004
Financial Results
RICHMOND, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
(NASDAQ:ONXX) reported a net loss of $13.1 million, or $0.38 per share, for the
second quarter ended June 30, 2004 compared with a net loss of $11.4 million,
or $0.48 per share, for the same quarter in 2003. The second quarter 2004
results reflect increased clinical development and marketing expenditures for
Onyx's lead product candidate, BAY 43-9006. An orally active small molecule
anticancer compound, BAY 43-9006, is being codeveloped with Bayer
Pharmaceuticals Corporation.
"The anticipated growth in operating expenses reflects the increased
expenditures from our Phase III trial and the initiation of other clinical
trials evaluating BAY 43-9006 in a number of different tumor types," said
Hollings C. Renton, Onyx's president and chief executive officer. "Though we
expect some quarter-to-quarter variability, the net loss for 2004 is estimated
to be in the range of $50 to $55 million as we continue these clinical trials
and incur premarketing expenses." Renton added, "Our financial performance for
the first half of 2004 is consistent with previously provided company guidance
and reflects our commitment to expediting the development of BAY 43- 9006."
For the quarters ended June 30, 2004 and 2003, Onyx reported no revenue. Total
operating expenses of $13.8 million increased by $2.5 million in the second
quarter as compared to the same period in the prior year. This change reflects
increased clinical development and marketing expenses for BAY 43- 9006.
Research and development costs were $9.8 million in the second quarter of 2004
compared to $6.7 million in the second quarter of 2003, an increase of $3.1
million over the comparable period last year. BAY 43-9006 development expenses
increased by $6.2 million while therapeutic virus expenses decreased by $3.1
million due to the termination of the program in 2003. Marketing costs
increased to $1.5 million in the second quarter of 2004 compared to $0.2
million in the second quarter of 2003 due to an increase in internal and
external resources allocated to BAY 43-9006. General and administrative costs
increased to $2.2 million in the second quarter of 2004 compared to $1.6
million in the second quarter of 2003. Restructuring charges related to the
2003 discontinuation of the therapeutic virus program decreased to $0.3 million
in the second quarter of 2004 as compared to $2.8 million in the same period in
the prior year.
As of June 30, 2004, the company had cash, cash equivalents, and marketable
securities of $237.2 million compared to $105.4 million at December 31, 2003.
The increase was due to a public offering completed in February 2004 which
resulted in net proceeds of $148.3 million to Onyx.
Six-month Results
For the six months ended June 30, 2004, the company reported a net loss of
$21.3 million, or $0.63 per share, compared with a net loss of $22.1 million,
or $0.95 per share, for the same period in 2003. There were no revenues
recorded in the first six months of 2004 and 2003. Operating expenses
increased by $0.4 million during the six-month period ended June 30, 2004 as
compared to the same period in the prior year.
Onyx's management will host a teleconference and webcast discussing the
company's second quarter and six-month 2004 financial results. The event will
be held today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Interested
parties may access the live webcast at: http://audioevent.mshow.com/179451 or
by dialing 706-679-4614 and using the passcode 9143944. A replay of the
presentation will be available on the Onyx website, or by dialing 706-645-9291,
approximately three hours after the teleconference concludes. The replay will
be available through September 9, 2004.
Onyx Pharmaceuticals is engaged in the development of novel cancer therapies
that target the molecular basis of cancer. With its collaborators, the company
is developing small molecule drugs, including BAY 43-9006 with Bayer
Pharmaceuticals Corporation. For more information about Onyx's pipeline and
activities, visit the company's website at http://www.onyx-pharm.com/.
This press release contains forward-looking statements regarding expectations
about the development of BAY 43-9006 and anticipated 2004 losses. These
forward-looking statements involve a number of risks and uncertainties that
could cause actual events to differ from the company's expectations. These
risks are addressed in the company's periodic reports filed with the Securities
and Exchange Commission, including but not limited to its Annual Report on Form
10-K filed on March 15, 2004 and its Quarterly Reports on Form 10-Q.
ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2004 2003 2004 2003
Total revenue $-- $-- $-- $--
Operating expenses:
Research and development 9,844 6,715 16,574 15,752
Marketing 1,471 229 1,760 309
General and administrative 2,229 1,563 3,915 2,865
Restructuring 258 2,759 258 3,201
Total operating expenses 13,802 11,266 22,507 22,127
Loss from operations (13,802) (11,266) (22,507) (22,127)
Interest income, net 696 135 1,220 308
Other income (expense) -- (275) -- (275)
Net loss $(13,106) $(11,406) $(21,287) $(22,094)
Basic and diluted net loss per
share $(0.38) $(0.48) $(0.63) $(0.95)
Shares used in computing basic
and diluted net loss per share 34,723 23,820 33,639 23,274
CONDENSED BALANCE SHEETS
(In thousands)
June 30, Dec. 31,
2004 2003
(unaudited) (1)
Assets
Cash, cash equivalents and marketable securities $237,245 $105,400
Other current assets 4,411 3,045
Total current assets 241,656 108,445
Property and equipment, net 268 285
Other assets 411 408
Total assets $242,335 $109,138
Liabilities and stockholders' equity
Current liabilities $17,237 $15,619
Advance from collaboration partner 20,000 20,000
Stockholders' equity 205,098 73,519
Total liabilities and stockholders' equity $242,335 $109,138
(1) Derived from the audited financial statements included in the
Company's Annual Report on Form 10-K for the year ended December 31,
2003.
DATASOURCE: Onyx Pharmaceuticals, Inc.
CONTACT: Julie Wood of Onyx Pharmaceuticals, Inc., +1-510-262-8757
Web site: http://www.onyx-pharm.com/